A study finds that engineered exosomes are effective in mice, but their potential use in humans raises safety questions.  

Nanoparticle-coated bacteria can capture tumor antigens and deliver them to immune cells, triggering a response that improved survival rates in mice.

Nanoparticle-coated bacteria carry cancer-derived proteins to dendritic cells, enabling the immune system to launch a response in a mouse model.

In vitro and mouse experiments show how cancer cells forced through tiny pores—mimicking the physical experience of metastasis—resisted programmed cell death and avoided detection by the immune cells that would normally kill them.

First, the genetically engineered cells became CD8⁺ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4⁺ helper T cells that continue to circulate in his body.

When coated with positively charged particles, the bacteria shuttled antigens out of tumors and activated the immune system, a study finds.

Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.

Several research groups have found that Toxoplasma gondii infection can ramp up antitumor immune responses in mice. Can the single-cell parasite be used to develop safe treatments for humans?

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.